Japan’s Mochida To Submit NDA In Japan For Epadel Switch OTC Drug
This article was originally published in PharmAsia News
Mochida Pharmaceutical will submit a new drug application in Japan for hyperlipidemia drug Epadel (eicosapentaenoic) switch drug within the year. Using positive data from clinical trials, the company aims for a rapid approval. Upon approval, Mochida's Epadel partner, Japanese major OTC drug maker Taisho Pharmaceutical plans to expand the product in the health supplements market among health sensitive consumers. (Click here for more - Japanese language
You may also be interested in...
Inovio forges ahead into Phase I trials with DNA-based vaccine candidate, but can it prove skeptics wrong?
Sandoz has appointed a new leader for its Japanese business following the acquisition of Aspen’s local operations, while Stada has brought in a former Sandoz and Pfizer executive to lead its Ciclum Farma unit in Portugal. Meanwhile, Julphar has a new CEO.
The impact of the coronavirus pandemic on investors’ portfolios was immediately apparent at the end of the first quarter of 2020. Equity market sell-offs are reflections of investors’ concern for future financial performance which, if material, may have to be announced early.